UBS Remains a Buy on Teva Pharmaceutical (TEVA)

In a report released today, Ashwani Verma from UBS maintained a Buy rating on Teva Pharmaceutical, with a price target of $36.00.

Claim 30% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Verma is a 4-star analyst with an average return of 8.0% and a 47.69% success rate. Verma covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, United Therapeutics, and Cytokinetics.

In addition to UBS, Teva Pharmaceutical also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Teva Pharmaceutical (NYSE: TEVA).

Based on Teva Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.71 billion and a net profit of $480 million. In comparison, last year the company earned a revenue of $4.23 billion and had a GAAP net loss of $217 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year. Earlier this month, Mark Sabag, the EVP, International Markets Commercial of TEVA sold 62,102.00 shares for a total of $1,871,754.28.